NASDAQ:VRAYViewray Stock Price, Forecast & News

Viewray's stock was trading at $1.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VRAY shares have increased by 23.7% and is now trading at $2.09. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viewray.

Viewray is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Viewray.

Viewray Inc (NASDAQ:VRAY) posted its quarterly earnings results on Thursday, April, 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.19). The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.47 million. Viewray had a negative return on equity of 71.37% and a negative net margin of 139.91%. View Viewray's earnings history.

Viewray issued an update on its FY 2020 After-Hours earnings guidance on Thursday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $58-95 million, compared to the consensus revenue estimate of $110.15 million.

10 Wall Street analysts have issued 1-year price objectives for Viewray's shares. Their forecasts range from $2.00 to $8.00. On average, they expect Viewray's share price to reach $5.17 in the next year. This suggests a possible upside of 147.2% from the stock's current price. View analysts' price targets for Viewray.

Headlines about VRAY stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viewray earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View the latest news aboutViewray.

Some companies that are related to Viewray include InMode (INMD), Natus Medical (NTUS), Zynex (ZYXI), AxoGen (AXGN), BioLife Solutions (BLFS), Stereotaxis (STXS), BioSig Technologies (BSGM), TransMedics Group (TMDX), Semler Scientific (SMLR), Cutera (CUTR), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), Fc Global Realty (FCRE) and IRIDEX (IRIX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Anavex Life Sciences (AVXL) and Inovio Pharmaceuticals (INO).

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Viewray's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hudson Executive Capital LP (8.84%), BlackRock Inc. (4.88%), Silvercrest Asset Management Group LLC (2.63%), State Street Corp (1.35%), Geode Capital Management LLC (1.07%) and Needham Investment Management LLC (0.75%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View institutional ownership trends for Viewray.

VRAY stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., Morgan Stanley, Ieq Capital LLC, Joel Isaacson & Co. LLC, Weiss Multi Strategy Advisers LLC, and Essex Investment Management Co. LLC. View insider buying and selling activity for Viewray.

VRAY stock was bought by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, BlackRock Inc., Needham Investment Management LLC, Silvercrest Asset Management Group LLC, State Street Corp, Geode Capital Management LLC, UBS Group AG, and Nuveen Asset Management LLC. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake, and Shahriar Matin. View insider buying and selling activity for Viewray.

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $2.09.

Viewray has a market capitalization of $308.06 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

The official website for Viewray is www.viewray.com.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]